Clinical Trials
10 trialsNCT06152575 2026-06-05
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
Phase 3 Recruiting
NCT01191060 2026-04-06
IFM/DFCI2009
University Hospital, Toulouse
Phase 3 Completed
NCT04751877 2026-02-10
Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).
Poitiers University Hospital
Phase 3 Active not recruiting
NCT01208662 2026-01-22
DFCI 10-106
Dana-Farber Cancer Institute
Phase 3 Active not recruiting
NCT01208766 2026-01-06
HO95
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Completed
NCT00773747 2021-04-30
Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01023308 2020-03-17
PANORAMA-1
Novartis
Phase 3 Completed
NCT01554852 2018-06-11
Myeloma XI
University of Leeds
Phase 3 Unknown
NCT00111748 2015-10-06
UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients
University of Arkansas
Phase 3 Completed
NCT00093028 2010-07-02
Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II
University of Arkansas
Phase 3 Completed